Been waiting to see if anybody else here is seeing the little hidden gem that I'm seeing in this PR...guess not. This PR mostly contains things we already knew but one thing in particular caught my eye here: ..................................................................................................................................... Legal Settlement On January 3, 2011, Viral Genetics settled the nearly 5 year-old lawsuit that was before the U. S. District Court for the Northern District of Illinois (No. 06 C 1813) regarding the Company's previous efforts in South Africa. This settlement frees up management time and Company resources that were previously consumed by the expensive litigation process and it allows Viral Genetics to continue the pursuit of the registration of an HIV/AIDS drug in Africa – the single largest potential market for such a product. See the Company's January 28, 2011 press release for more information. ..................................................................................................................................... This line especially: "allows Viral Genetics to continue the pursuit of the registration of an HIV/AIDS drug in Africa"
I'm not fully up2speed on the international drug approval process...I do know that their are international protocals on recognized drug trial standards , however , it appears very clear in looking at this statement that Viral fully intends to pursue the "registration" of their AIDS/HIV drug therapy in Africa , asap. In short; it seems entirely possible (to me) that So. Africa could-well approve VRAL's AIDS therapy for use in their own country on an independent basis. VRAL has already conducted successful trials in So. Africa: "2006 – Completed double-blind, placebo-controlled study of VGV-1 (South African) • 137-patient study designated “Phase III” by South African Medicines Control Council • No apparent toxicities or significant adverse events related to drug observed • 22% showed significant decrease in HIV viral load 100 days after treatment. • Stronger results in later-stage, sicker patients – consistent with prior studies. " **source; http://www.viralgenetics.com/about/history.php
Beyond that & where we go from here: "Development: VGV-X: HIV/AIDS Six international, human clinical trials found that our first-generation HIV/AIDS drug compound significantly reduced the viral load by over 90-95% in some patients. That therapy led to the development of a second generation TPT drug compound called VGV-X. We believe that VGV-X may address the reason that our first HIV/AIDS drug reduced the viral load in some patients, but not others. Preparing this therapeutic approach for human clinical trials is a top priority.
Current antiviral treatments for HIV and AIDS are drug combinations that are expensive, difficult to access in many areas of the world, and accompanied by a number of complications, including moderate to severe side effects, onerous dosing regimens, multiple drug interactions, and the development of drug resistant strains of the HIV virus. Based on our experience with an earlier version of VGV-X, we are hopeful that it will continue to demonstrate only moderate side effects and a less onerous dosing regimen.
With over 40 million cases of HIV in the world and growing, including over 25 million in Sub-Saharan Africa alone, we believe that such a therapy would be of significant interest." **source; http://www.viralgenetics.com/development/hiv-aids.php
News 
Market Data 
Discover 
AI
